ArticleThoracic cancer2020

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

Alejandro Ruiz-Patiño et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.